AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine (CCNU)
Description: Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine (CCNU)
Description: Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
Study NCT04421378 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fractionated Radiation therapy (RT)
Description: Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
Study NCT04421378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Fractionated Radiation therapy (RT)
Description: Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
Study NCT04421378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTField
Description: Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
Study NCT03262337 — intervention group
Intervention type: OTHER
Intervention: none, this is an observational study
Description: none, this is an observational study
Study NCT04003311 — intervention group
Intervention type: DEVICE
Intervention: Comprehensive Primary Micro Stem
Description: Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
Study NCT04003311 — intervention group
Intervention type: DEVICE
Intervention: Comprehensive Anatomic Versa-Dial Titanium Humeral Head
Description: Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
Study NCT02728921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Albumin infusion 30 min
Description: Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
Study NCT02728921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Albumin infusion 3 hours
Description: Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
Study NCT03544528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration
Description: Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
Study NCT02406014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate Gel, 0.015%
Description: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
Study NCT02406014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium gel 3%
Description: Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
Study NCT03029780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opdivo
Description: Specified dose on specified days
Study NCT03029780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yervoy
Description: Specified dose on specified days
Study NCT01015261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Allogenic Bone Marrow Transplantation
Study NCT01015261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1. Cyclophosphamide 1200 mg/m2 D15~2. Daunorubicin 45 mg/m2 D15-D18~3. Vincristine 1 mg/m2 D15, D22~4. Dexamethasone 24 mg/d D12-D28
Study NCT04487847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007 PET/CT
Description: 18F-PSMA-1007 PET/CT
Study NCT03391713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Poster
Description: The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
Study NCT01754779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets twice daily of matching placebo during the placebo phase.
Study NCT01754779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citric Acid
Description: 3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)
Study NCT01754779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: 2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)
Study NCT01261767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for subcutaneous (under the skin) injection
Study NCT01592240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Placebo Q28d
Study NCT01592240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg PF-04950615 (RN316)
Description: PF-04950615 200 mg, Q28d
Study NCT01592240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg PF-04950615 (RN316)
Description: PF-04950615 300 mg, Q28d
Study NCT00593112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02152423 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LOVENOX
Description: LMWH
Study NCT02152423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENOXAMED
Description: LMWH
Study NCT03893929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: New Biological markers for prostate cancer diagnosis and management
Description: To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
Study NCT02517515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study NCT02517515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
Study NCT03453463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 3x week predominately resistance exercise for 18 months
Study NCT00636623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pilates exercises
Description: 15 FM patients participated in the PE programme three times a week during a 4-week period
Study NCT02639026 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
Study NCT02639026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: 20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
Study NCT02639026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 1 mg/kg every 4 weeks for 4 doses
Study NCT02206152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
Study NCT02206152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01560377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT Endoscopic Fluorescence Imaging System
Description: The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
Study NCT04506580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture
Description: DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
Study NCT01227564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Phosphate buffered saline (PBS)
Description: Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
Study NCT05193357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based intermittent pneumatic compression (IPC) device
Description: During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
Study NCT04256889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nfant(R) feeding system
Description: Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
Study NCT00610584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
Study NCT00610584 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: minimal (sham)acupuncture
Description: arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
Study NCT03047603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PIVKA-II
Description: Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
Study NCT01207934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline placebo
Study NCT01207934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose leptin
Description: 30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
Study NCT01207934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose leptin
Description: 80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
Study NCT00636623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Connective tissue massage
Description: 21 patients received CTM, three times a week during a 4-week period
Study NCT04142463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care pathway
Description: A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
Study NCT04102540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infographic intervention
Description: Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
Study NCT00932490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Coaching
Description: Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
Study NCT01611103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
Study NCT01611103 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
Study NCT01443429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beraprost sodium(BPS)
Study NCT00074763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
Study NCT00649974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride Tablets 1000 mg
Description: 1000mg, single dose fasting
Study NCT04291300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177-PSMA-I&T
Description: 4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
Study NCT00818038 — intervention group
Intervention type: DRUG
Intervention: BG0002 (natalizumab)
Description: Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
Study NCT02446652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine/Magnesium
Description: (Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
Study NCT02446652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (orally) starting 1 week before the first day of the QT
Study NCT02446652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5 AUC 1 hour/day 1 for every 21 days for 6 cycles
Study NCT02446652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: 5 AUC 1 hour/day 1 for every 21 days for 6 cycles
Study NCT02446652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
Study NCT02446652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
Study NCT00872898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine - Extended Release (ER)
Description: Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
Study NCT00872898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, once daily, oral administration.
Study NCT03065803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal plate expansion technique for dental socket preservation
Description: An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0).
Study NCT03065803 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Guided bone regeneration technique for post-extraction dental socket preservation
Description: After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
Study NCT04570449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg capsule
Study NCT04570449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: fluoxetine placebo capsule
Study NCT01422304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex 4 mg/kg intravenously
Study NCT01422304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neostigmine and glycopyrrolate or atropine
Description: Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
Study NCT02390999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 48 hours of therapeutic hypothermia
Study NCT00951873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
Study NCT00951873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
Study NCT00951873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
Study NCT01270555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Description: 100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
Study NCT02289014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online stress Management program
Description: Active treatment group
Study NCT00610584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetirizine dihydrochloride (rescue medication)
Description: arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
Study NCT00907062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Description: 60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
Study NCT03785743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLPD Surgery
Description: TLPD
Study NCT03785743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OPD Surgery
Description: OPD
Study NCT01692873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suspected pancreatic tumor
Description: Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
Study NCT03949491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D medical models
Description: Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction